Poll Reveals Data Management Inefficiencies Lengthen Drug Discovery Process
WESTBOROUGH, MA (June 3, 2002) - Inefficiencies in data management and a significant increase in the amount of data generated in today's modern laboratories are contributing to a slower drug discovery process, suggests a recent poll conducted by NuGenesis Technologies Corporation. The poll was taken by attendees of the company's Web seminar series, "Managing the Drug Discovery and Data Explosion" held earlier this year.
Inefficiencies in Data Management
The background of the participants in the poll included drug discovery groups in the life sciences, such as assay development, target identification and validation, and bio-analytical. Of the 137 attendees polled, 58 percent noted that they do not have a formal method to organize data electronically, and 22 percent stated that they still keep records by cutting and pasting into a notebook.
"All of the relevant information and data collection will ultimately be automated," explains John Helfrich, development manager for the drug discovery and development applications group at NuGenesis Technologies Corporation. "We're probably looking out five years, maybe even 10 years before 90 percent of the research population is finally transitioned to an electronic data management system."
Many laboratories are in the process of converting from a paper-based environment to an electronic one, to be compliant with current FDA legislation and to allow scientists to better manage their research data, and promotes sharing information across an organization. Data that is maintained in an electronic format can be interpreted, analyzed, reported, reviewed and used to make faster and more informed decisions - on whether to continue or abandon a line of research, for example.
Data Explosion
Nine out of ten poll respondents noted that their data management needs had risen dramatically over a year's time - increasing by half for 25 percent and doubling for 20 percent. One in three respondents cited a 25 percent increase in data management needs.
"The drug discovery arena is seeing an explosion of data today unlike anything that has been experienced before," comments Mr. Helfrich. "It has become essential to automatically capture the whole data profile from target identification, high throughput screening, medicinal chemistry and preclinical experiments into a single repository, so the research team can access and analyze the information in the most efficient way possible".
NuGenesis Technologies has developed the NuGenesis® Scientific Data Management System (SDMS) that captures data generated from any analytical instrument into a repository where scientists can locate, access, analyze and share it in order to make decisions quickly. The NuGenesis SDMS repository can also accept data from other software applications throughout the organization, for an integrated approach to data management.
NuGenesis Web seminars are scheduled regularly to assist scientists with their data management needs and to demonstrate how to effectively protect and manage intellectual property as well as comply with new regulatory guidelines (21 CFR Part 11). More information on NuGenesis Technologies seminars can be found at www.nugenesis.com.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Protein found to regulate spread of pancreatic cancer cells
Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics
Gen-Probe Granted Summary Judgment in Enzo Patent Lawsuit
Alnylam Grants Ambion License to Fundamental RNAi Patents for Applications in the Research Products Market
Positive top-line phase III data in type 2 diabetes achieved for lixisenatide once-daily vs. exenatide twice-daily - Lixisenatide meets primary efficacy endpoint with fewer hypoglycaemias
Researchers discover how mutations in presenilin gene cause early onset Alzheimer's disease
Researchers find that one type of stem cell creates a niche for another type in bone marrow - Understanding how blood stem cells are maintained within the niche offers new opportunities to exploit them therapeutically
Protein visualization company Sidec raises 5 MUSD with US and Swedish investors
Boehringer Ingelheim and Structural Bioinformatics, Inc. agree on research collaboration involving new anti-HIV compound/leads
RMIT sells toxicology testing business to vivoPharm
